CN104918622A - 用于对抗黑色素瘤细胞的飞燕草素 - Google Patents

用于对抗黑色素瘤细胞的飞燕草素 Download PDF

Info

Publication number
CN104918622A
CN104918622A CN201380064588.0A CN201380064588A CN104918622A CN 104918622 A CN104918622 A CN 104918622A CN 201380064588 A CN201380064588 A CN 201380064588A CN 104918622 A CN104918622 A CN 104918622A
Authority
CN
China
Prior art keywords
delphinidin
cells
composition
sbe
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380064588.0A
Other languages
English (en)
Chinese (zh)
Inventor
诺伯特·若维尔
延斯·布若斯凯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapiotec GmbH
Original Assignee
Sapiotec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapiotec GmbH filed Critical Sapiotec GmbH
Publication of CN104918622A publication Critical patent/CN104918622A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
CN201380064588.0A 2012-12-11 2013-11-28 用于对抗黑色素瘤细胞的飞燕草素 Pending CN104918622A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102012222777 2012-12-11
DE102012222777.6 2012-12-11
EP13150909 2013-01-11
EP13150909.3 2013-01-11
PCT/EP2013/074957 WO2014090583A1 (de) 2012-12-11 2013-11-28 Delphinidin zur bekämpfung von melanomzellen

Publications (1)

Publication Number Publication Date
CN104918622A true CN104918622A (zh) 2015-09-16

Family

ID=49679524

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380064588.0A Pending CN104918622A (zh) 2012-12-11 2013-11-28 用于对抗黑色素瘤细胞的飞燕草素
CN201380064614.XA Pending CN104936601A (zh) 2012-12-11 2013-11-28 用于对抗黑色素瘤细胞的飞燕草素

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380064614.XA Pending CN104936601A (zh) 2012-12-11 2013-11-28 用于对抗黑色素瘤细胞的飞燕草素

Country Status (8)

Country Link
US (2) US9511047B2 (cg-RX-API-DMAC7.html)
EP (2) EP2931286B1 (cg-RX-API-DMAC7.html)
JP (2) JP6234475B2 (cg-RX-API-DMAC7.html)
KR (2) KR102164174B1 (cg-RX-API-DMAC7.html)
CN (2) CN104918622A (cg-RX-API-DMAC7.html)
CA (2) CA2893883A1 (cg-RX-API-DMAC7.html)
HK (1) HK1215392A1 (cg-RX-API-DMAC7.html)
WO (2) WO2014090583A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
JP6234475B2 (ja) * 2012-12-11 2017-11-22 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ メラノーマ細胞に対抗するためのデルフィニジン

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050013880A1 (en) * 2003-03-06 2005-01-20 Magnuson Bernadene Ann Anthocyanin-rich compositions and methods for inhibiting cancer cell growth
CN1696304A (zh) * 2004-05-13 2005-11-16 深圳新鹏生物工程有限公司 重组人可溶性肿瘤坏死因子相关凋亡诱导配体制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946228A (ja) 1982-09-08 1984-03-15 Zeria Shinyaku Kogyo Kk 生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法
HU199444B (en) 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
GB8907008D0 (en) 1989-03-28 1989-05-10 Inverni Della Beffa Spa Intermediates useful for the synthesis for delphinidin chloride
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
ZA962214B (en) 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
CA2225378C (en) * 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
GB2307176A (en) 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
JP4101346B2 (ja) 1998-02-18 2008-06-18 ダイセル化学工業株式会社 酸化触媒系及びそれを用いた酸化方法
WO1999042111A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
GB2350297A (en) 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
JP2003506458A (ja) 1999-08-11 2003-02-18 ジョセフ ピサ， シクロデキストリン誘導体の包接複合体形成の増強
WO2001030391A2 (en) 1999-10-27 2001-05-03 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
ATE309262T1 (de) * 2000-09-12 2005-11-15 Meiji Seika Kaisha Verfahren zur herstellung von aufgereinigtem anthocyanin und kristallines anthocyanin
EP1383445A4 (en) 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2003171274A (ja) 2001-12-07 2003-06-17 Tomihiko Higuchi 薬剤耐性菌感染症治療のための医薬組成物および消毒剤
WO2003063824A2 (en) 2002-02-01 2003-08-07 Shimoda Biotech (Pty) Ltd Pharmaceutical composition
JP2004238336A (ja) * 2003-02-07 2004-08-26 Sanei Gen Ffi Inc 水易溶性包接フラボノイド類の製造方法
ES2584183T3 (es) 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
US20090192230A1 (en) 2004-01-14 2009-07-30 Koichi Takeda Propofol-containing fat emulsion preparation
CN1317961C (zh) 2004-03-25 2007-05-30 吴朝琴 冻干草莓加工工艺
WO2006076387A2 (en) * 2005-01-11 2006-07-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Cyanidin-3-glucoside as an anti-neoplastic agent
DE102005017775A1 (de) 2005-04-13 2006-10-19 Schering Ag Komplexe aus Vitamin D-Verbindungen oder deren Analoga mit einem 5Z,7E,10(19)-Trien-System und methlierten Derivaten des ß-Cyclodextrins
KR100733913B1 (ko) * 2005-08-30 2007-07-02 한국화학연구원 안토시아닌을 포함하는 뇌세포 보호제와 뇌경색 및 뇌졸중예방 또는 치료제
US7645748B2 (en) 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
US9000048B2 (en) 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
KR100756656B1 (ko) 2006-12-12 2007-09-10 한국화학연구원 안토시아닌을 포함하는 뇌경색 또는 뇌졸중 예방 및 개선용건강식품
KR100880876B1 (ko) 2007-04-11 2009-01-30 경상대학교산학협력단 검정콩 껍질로부터 추출한 안토시아닌을 함유하는 피판이나조직의 허혈-재관류 손상의 예방 또는 치료용 의약 조성물
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
JP5574600B2 (ja) 2007-12-17 2014-08-20 日本製薬工業株式会社 吸収性骨疾患の予防・治療剤
EP2106786A1 (de) 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2010110328A1 (ja) 2009-03-25 2010-09-30 三栄源エフ・エフ・アイ株式会社 水易溶性イソクエルシトリン組成物
EP2437770A4 (en) 2009-06-05 2013-11-06 Univ Colorado Regents ANTIMICROBIAL PEPTIDES
KR101625882B1 (ko) 2009-10-21 2016-05-31 마뀌 뉴 라이프 에스. 에이. 안토시아니딘을 포함하는 조성물 및 이용방법
EP2345427A1 (de) 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
CA2792733C (en) 2010-03-13 2015-06-02 Eastpond Laboratories Limited Fat-binding compositions comprising .alpha.- or .beta.-cyclodextrin
DE102010042615A1 (de) 2010-10-19 2012-04-19 Wacker Chemie Ag 1:1, 2:1- oder 3:1-Komplex bestehend aus einem Cyclodextrin oder Cyclodextrinderivat und einem halogeniertem Ether, seine Herstellung und seine Verwendung als Schlafmittel
CA2822995C (en) 2010-12-31 2021-05-11 Eastpond Laboratories Limited Cellular hydration compositions containing cyclodextrins
EP2484350B1 (de) 2011-02-04 2016-04-20 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung, enthaltend einen Komplex eines Propofolsalzes mit einem Cyclodextrin
EP2854553B1 (de) 2012-03-30 2016-12-21 SapioTec GmbH Verwendung von delphinidin gegen staphylococcus aureus
US20150087822A1 (en) * 2012-03-30 2015-03-26 Sapiotec Gmbh Anthocyanidin complex
KR20150070303A (ko) 2012-10-17 2015-06-24 자피오텍 게엠베하 다발성 골수종 치료를 위한 안토시아니딘 복합제
US9925274B2 (en) * 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
JP6234475B2 (ja) * 2012-12-11 2017-11-22 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ メラノーマ細胞に対抗するためのデルフィニジン
EP2913050A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
EP2913366A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Anthocyanidin-Komplex

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050013880A1 (en) * 2003-03-06 2005-01-20 Magnuson Bernadene Ann Anthocyanin-rich compositions and methods for inhibiting cancer cell growth
CN1696304A (zh) * 2004-05-13 2005-11-16 深圳新鹏生物工程有限公司 重组人可溶性肿瘤坏死因子相关凋亡诱导配体制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUI-PEI HUANG等: "Chemoinhibitory Effect of Mulberry Anthocyanins on Melanoma Metastasis Involved in the Ras/PI3K Pathway", 《JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY》 *
LI-SHU WANG等: "Anthocyanins and their role in cancer prevention", 《CANCER LETTERS》 *
林晓霞等: "中药花色素类成分抗癌研究进展", 《中国中药杂志》 *

Also Published As

Publication number Publication date
JP2016502985A (ja) 2016-02-01
JP2016502984A (ja) 2016-02-01
EP2931287B1 (de) 2017-10-04
KR20150107742A (ko) 2015-09-23
US9949947B2 (en) 2018-04-24
US20150320719A1 (en) 2015-11-12
CA2893881C (en) 2020-09-22
CA2893881A1 (en) 2014-06-19
CA2893883A1 (en) 2014-06-19
CN104936601A (zh) 2015-09-23
JP6234475B2 (ja) 2017-11-22
JP6234476B2 (ja) 2017-11-22
EP2931286B1 (de) 2017-10-04
US9511047B2 (en) 2016-12-06
WO2014090583A1 (de) 2014-06-19
EP2931287A1 (de) 2015-10-21
US20150328336A1 (en) 2015-11-19
KR102164174B1 (ko) 2020-10-12
HK1215392A1 (zh) 2016-08-26
WO2014090586A1 (de) 2014-06-19
KR20150107741A (ko) 2015-09-23
EP2931286A1 (de) 2015-10-21
HK1216229A1 (zh) 2016-10-28

Similar Documents

Publication Publication Date Title
Wadhwa et al. Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro
Su et al. Inhalation of tetrandrine-hydroxypropyl-β-cyclodextrin inclusion complexes for pulmonary fibrosis treatment
Hu et al. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells
Joseph et al. Galactoxyloglucan-modified nanocarriers of doxorubicin for improved tumor-targeted drug delivery with minimal toxicity
Zou et al. Natural antibacterial agent-based nanoparticles for effective treatment of intracellular MRSA infection
Lan et al. Dual-responsive curcumin-loaded nanoparticles for the treatment of cisplatin-induced acute kidney injury
Yi et al. Enhanced response of tamoxifen toward the cancer cells using a combination of chemotherapy and photothermal ablation induced by lentinan-functionalized multi-walled carbon nanotubes
Azhar et al. Suppressing growth, migration, and invasion of human hepatocellular carcinoma HepG2 cells by Catharanthus roseus‑silver nanoparticles
Park et al. Targeting and synergistic action of an antifungal peptide in an antibiotic drug-delivery system
JP5663741B2 (ja) アミノ酸抱合シアノアクリレートポリマー粒子
Groer et al. Intratumoral cancer chemotherapy with a carrier-based immunogenic cell death eliciting platinum (IV) agent
Wang et al. Salinomycin nanocrystals for colorectal cancer treatment through inhibition of Wnt/β-catenin signaling
Xiao et al. Precision delivery of binary cooperative nanodrugs self-assembled by berberine glycyrrhetinic acid salts for hepatocellular carcinoma treatment
Wu et al. Fluorescent hyaluronic acid nanoprodrug: A tumor-activated autophagy inhibitor for synergistic cancer therapy
CN110101685A (zh) 一种仿生纳米药物、其制备方法及应用
Li et al. Erythrocyte Membrane-Camouflaged Xanthohumol Nanoparticles Mitigate Doxorubicin-Induced Cardiotoxicity by Inhibiting Ferroptosis
CN104936601A (zh) 用于对抗黑色素瘤细胞的飞燕草素
CN104780925A (zh) 用于治疗多发性骨髓瘤的花青素络合物
Zhang et al. Integrated traditional Chinese and western medicine modulator for overcoming the multidrug resistance with carbon nanotubes
CN109646684B (zh) 环孢菌素h环糊精及其用途
Abou Zaid Biochemical study on the effect of cetyl trimethyl ammonium bromide surfactant coated spirulina zinc oxide nanocomposite as antimammary carcinogenesis in rats
RASHMI IN VITRO ANTICANCER ACTIVITY OF 6–THIOGUANINE AND 6-THIOGUANINE LOADED CHITOSAN NANOPARTICLES WITH OR WITHOUT CURCUMIN AND PHARMACOKINETIC STUDIES IN RATS
Shi Synergistic Active Targeting to B16F10 Tumors by αvβ3/CD44-Targeted Nanoparticles Loaded with Docetaxel
HK1216229B (en) Delphinidin for combating melanoma cells

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150916